Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096437 | 0.88 | PRNP (0.36) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL4869350 | 0.79 | PARP10 (0.41) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL2880311 | 0.79 | PARP10 (0.41) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL12525236 | 0.79 | PARP10 (0.41) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL8648955 | 0.79 | PARP10 (0.41) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL7218785 | 0.76 | ACHE (0.48) | ALDH1A1MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL3345163 | 0.76 | PARP10 (0.39) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL12525232 | 0.75 | HTR2C (0.46) | PARP10PARP11PARP1MAPTHTR2A | |
| Hydrochloric Acid SCHEMBL4866638 | 0.75 | ACHE (0.47) | ALDH1A1MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL28204154 | 0.75 | PARP10 (0.38) | PARP10PARP11PARP1PNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319100-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-7205306-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1392309-B1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1392309-A4 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| CN-1527710-A | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | ����˹�ж�-����˹˹����ҩƷ��˾ | 2004-09-08 | — | — | CN | disclosed |
| EP-1392309-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030171380-A1 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-09-11 | — | — | US | disclosed |
| US-6525056-B2 | A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| WO-2002092090-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1012151-B1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| CN-1278819-A | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating and stress-related | DU PONT PHARM CO (US) | 2001-01-03 | — | — | CN | disclosed |
| EP-1012151-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | Dupont Pharmaceuticals Company (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011643-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171380-A1 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | CRH, CRHR1, CRHR2 | PARP10 3194/4885PARP11 3706/4885PARP1 3808/4885 |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | CRH, CRHR1, CRHR2 | PARP10 3101/4885PARP11 3736/4885PARP1 3794/4885 |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | CRH, CRHR1, CRHR2 | PARP10 1661/4885PARP11 1248/4885PARP1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.